NeoGenomics, Inc. (NASDAQ:NEO) Receives $20.20 Average Price Target from Analysts

NeoGenomics, Inc. (NASDAQ:NEO) has been assigned an average rating of “Moderate Buy” from the eleven analysts that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $20.20.

A number of research firms recently commented on NEO. The Goldman Sachs Group decreased their target price on NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Benchmark downgraded NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price target on shares of NeoGenomics in a report on Friday, January 10th. Jefferies Financial Group began coverage on NeoGenomics in a report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price target for the company. Finally, Bank of America boosted their price target on NeoGenomics from $18.00 to $19.00 and gave the company a “neutral” rating in a report on Friday, December 13th.

Institutional Trading of NeoGenomics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of NeoGenomics by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 14,239,887 shares of the medical research company’s stock worth $234,673,000 after purchasing an additional 195,793 shares in the last quarter. State Street Corp increased its position in shares of NeoGenomics by 1.6% during the third quarter. State Street Corp now owns 4,958,582 shares of the medical research company’s stock worth $73,139,000 after purchasing an additional 80,449 shares in the last quarter. Greenhouse Funds LLLP increased its position in shares of NeoGenomics by 5.3% during the fourth quarter. Greenhouse Funds LLLP now owns 4,701,897 shares of the medical research company’s stock worth $77,487,000 after purchasing an additional 237,491 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of NeoGenomics by 2.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,436,858 shares of the medical research company’s stock worth $56,645,000 after purchasing an additional 78,211 shares in the last quarter. Finally, First Light Asset Management LLC increased its position in shares of NeoGenomics by 3.0% during the fourth quarter. First Light Asset Management LLC now owns 3,167,585 shares of the medical research company’s stock worth $52,202,000 after purchasing an additional 91,030 shares in the last quarter. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

NeoGenomics Trading Up 3.7 %

NeoGenomics stock opened at $14.42 on Thursday. The company has a quick ratio of 1.91, a current ratio of 1.99 and a debt-to-equity ratio of 0.37. NeoGenomics has a 52 week low of $12.13 and a 52 week high of $19.11. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of -23.64 and a beta of 1.23. The stock has a 50-day moving average price of $15.70 and a 200 day moving average price of $15.60.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.